

Substitute for form 1009-A PTO

MAR 19 2004  
PATENT & TRADEMARK OFFICE  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

|       |   |    |   |                     |          |
|-------|---|----|---|---------------------|----------|
| Sheet | 1 | of | 1 | Attorney Docket No. | 98-385-H |
|-------|---|----|---|---------------------|----------|

**Complete if Known**

|                      |            |
|----------------------|------------|
| Application No.      | 09/899,422 |
| Filing Date:         | 7-3-01     |
| First Named Inventor | Hauptmann  |
| Group Art Unit       | 1646       |
| Examiner Name        | E. O'Hara  |

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | U.S. Patent Document |                                      | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines<br>Where Relevant<br>Passages or Figures<br>Appear |
|--------------------|-----------------------|----------------------|--------------------------------------|---|---|--|
|                    |                       | Number               | Kind Code <sup>2</sup><br>(if known) |   |   |  |
|                    |                       |                      |                                      |   |   |  |
|                    |                       |                      |                                      |   |   |  |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                      | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines<br>Where Relevant<br>Passages or Figures<br>Appear | T <sup>6</sup> |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|--|----------------|
|                    |                       | Office <sup>3</sup>     | Number <sup>4</sup> | Kind Code <sup>5</sup><br>(if known) |   |   |  |                |
| EA                 |                       | DE                      | 3913101.7           | A1                                   | Boehringer Ingelheim International GmbH         |   |  |                |
|                    |                       |                         |                     |                                      |   |   |  |                |

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

|                    |                       |   |                |
|--------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. <sup>1</sup> | Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T <sup>2</sup> |
| EA                 |                       | HELLER et al., "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor," <i>Proc. Natl. Acad. Sci.</i> 87: 6151-55 (1990).  |                |
|                    |                       | PEPPEL et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> 174:1483-89 (1991).  |                |
|                    |                       | TSUJIMOTO et al., "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells," <i>Archives of Biochemistry</i> 249(2):563-568(1986).   |                |
|                    |                       | POWELL et al., "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS," <i>Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine.</i> pgs 355-69.  |                |
|                    |                       | RHEIN et al., "Another Sepsis Drug Down-Immune TNF Receptor," <i>Biotechnology Newswatch</i> , pg. 1,3 (Monday, October 4, 1991).   |                |
|                    |                       | VILCEK et al., "Tumor Necrosis Factor: Receptor Binding and Mitogenic Action in Fibroblasts," <i>J. Cell. Physiol.</i> 5:57-61 (1987).  |                |
| ↓                  |                       | SMITH et al., "Species Specificity of Human and Murine Tumor Necrosis Factor," <i>The Journal of Biological Chemistry</i> , 251(32):14871-148874 (1986).  |                |

|                    |                         |                 |         |
|--------------------|-------------------------|-----------------|---------|
| Examiner Signature | <i>Eileen B. O'Hara</i> | Date Considered | 5/21/04 |
|--------------------|-------------------------|-----------------|---------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231